项目编号：DT-BD-20200418-014
Project Number: DT-BD-20200418-014
项目内容：中国公司收购糖尿病类、心血管类已通过一致性评价品种
Request：Chinese companies would like to acquire diabetes and cardiovascular drugs that have passed BE
目标领域：糖尿病类、心血管类
Target area: Diabetes, cardiovascular
目前阶段：通过一致性评价
Current stage: Pass the BE
药物类别：小分子、大分子药物
Drug category: Small molecule, Large molecule
目标权益：中国大陆或大中华区
Target right: Mainland China, Greater China
如果您对该合作机会感兴趣，欢迎与我们联系！我们将与您详细探讨。谢谢！
If you are interested in this collaboration opportunity, please contact us. We will discuss with you in details. Thank you very much!
联系人 (Contact)：Will
电话 (Mobile)：13564569657
微信 (Wechat)：27674131
邮箱 (E-mail)：BD@drugtimes.cn
邮件主题请注明：项目编号：DT-BD-20200418-014
In the e-mail subject, please include “Project Number: DT-BD-20200418-014”
发布者：药时代，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
